Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Massive COPD study aims to unlock secrets of lung disease

NCT ID NCT01969344

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows nearly 3,000 people with COPD (a chronic lung disease) over several years to understand how the disease progresses and what factors influence it. Researchers measure lung function, analyze mucus, and track environmental exposures like air pollution. The goal is to find better ways to predict and measure COPD worsening, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,981 people

The number who actually took part.

Start date

Nov 2010

Expected to finish

Jun 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Never-smokers, current and former smokers without COPD, and current and former smokers with COPD with access to one of the study clinical centers.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Between 40 and 80 at baseline visit * Never smokers: \<1 pack-year history of smoking * Never smokers: Must meet lung function criteria based on spirometry without inhaled bronchodilators * Current or former smokers: \>20 pack-year history of smoking * Current or former smokers: Must meet lung function criteria based on spirometry with inhaled bronchodilators Exclusion Criteria: * Dementia or other cognitive dysfunction which in the opinion of the investigator would prevent the participant from consenting to the study or completing study procedures * Plans to leave the area in the next 3 years * Smoking history of \> 1 pack-year but \<21 pack-years * BMI \> 40 kg/m2 at baseline exam * Prior significant difficulties with pulmonary function testing * Hypersensitivity to or intolerance of albuterol sulfate or ipratropium bromide or propellants or excipients of the inhalers * Non-COPD obstructive lung disease, severe kyphoscoliosis, neuromuscular weakness, or other conditions, including clinically significant cardiovascular and pulmonary disease, that, limit the interpretability of the pulmonary function measures. * History of Interstitial lung disease * History of Lung volume reduction surgery or lung resection * History of lung or other organ transplant * History of endobronchial valve therapy * History of large thoracic metal implants (e.g., AICD (automatic implantable cardioverter/defibrillator) and/or pacemaker) * Currently taking \>=10mg a day/20mg every other day of prednisone or equivalent systemic corticosteroid * Currently taking any immunosuppressive agent * Current illicit substance abuse, excluding marijuana * History of or current use of IV Ritalin * History of or current use of heroin * History of illegal IV drug use within the last 10 years or more than 5 instances of illegal IV drug use ever * Known HIV/AIDS infection * History of lung cancer or any cancer that spread to multiple locations in the body * History of or current exposure to chemotherapy or radiation treatments that, in the opinion of the investigator, limits the interpretability of the pulmonary function measures. * Diagnosis of unstable cardiovascular disease including myocardial infarction in the past 6 weeks, uncontrolled congestive heart failure, or uncontrolled arrhythmia * Any illness expected to cause mortality in the next 3 years * Active pulmonary infection, including tuberculosis * History of pulmonary embolism in the past 2 years * Known diagnosis of primary bronchiectasis * Currently institutionalized (e.g., prisons, long-term care facilities) * Known to be a first degree relative of another, already enrolled participant (i.e., biological parent, biological sibling) * Never smokers only: Current diagnosis of asthma * Women only: Cannot be pregnant at baseline or plan to become pregnant during the course of the study Temporal Exclusion Criteria for SPIROMICS III: * Participants who present with a pulmonary exacerbation, either solely participant-identified or that has been clinically treated, in the last six weeks, can complete the study visit once a six-week window has passed. * Participants who present with an upper respiratory infection, either solely participant-identified or that has been clinically treated, in the last six weeks, can complete the study visit once a six-week window has passed. * Participants who present with current use of acute antibiotics or steroids can complete the study visit ≥30 days after discontinuing acute antibiotics/steroids. This does not apply to participants who are on chronic prednisone therapy of \<10 mg per day or \<20 mg every other day or participants who are currently on chronic, prophylactic, or suppressive antibiotic therapy. * Participants who present with a myocardial infarction or eye, chest or abdominal surgery within six weeks can complete the study visit after a six-week window has passed. * Female participants who present \<3 months after giving birth will be asked to schedule the visit once three months have passed post-delivery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic bronchitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Columbia University

    New York, New York, 10032, United States

  • Johns Hopkins University

    Baltimore, Maryland, 21224, United States

  • Mayo Clinic Arizona

    Scottsdale, Arizona, 85259, United States

  • National Jewish Health

    Denver, Colorado, 80206, United States

  • Temple University

    Philadelphia, Pennsylvania, 19140, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35249, United States

  • University of California at Los Angeles

    Los Angeles, California, 90095, United States

  • University of California at San Francisco

    San Francisco, California, 94143, United States

  • University of Illinois at Chicago

    Chicago, Illinois, 60612, United States

  • University of Iowa

    Iowa City, Iowa, 52242, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of Utah

    Salt Lake City, Utah, 84132, United States

  • Wake Forest University

    Winston-Salem, North Carolina, 27157, United States

  • Weill Cornell Medicine

    New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.